Trials / Terminated
TerminatedNCT02153840
Clinical Trial of PSORI-CM01（YXBCM01） Granule to Treat Stable Plaque Psoriasis
A Double-blind, Randomized, Placebo-controlled Trial of PSORI-CM01（YXBCM01） Granule for Stable Plaque Psoriasis
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Chinese herbal PSORI-CM01（YXBCM01） granule for stable plaque psoriasis, with blood stasis syndrome of Chinese Medicine.
Detailed description
Psoriasis is an immune-abnormal, chronic, proliferative skin disease characterized by scaly, erythematous patches and papules. An epidemiological survey found Chinese prevalence showed an upward trend in recent years. The disease has great influence on patients' appearance,health and quality of life. Some Chinese Herbal Medicine (CHM) therapies have shown long lasting therapeutic effect on controlling psoriasis vulgaris and with minimal side effects.CHM can alleviate the symptoms effectively,and reduce the recurrence rate of diseases. PSORI-CM01（YXBCM01）granule is one kind of CHM which is observed effective and safe to treat stable stable plaque psoriasis with blood stasis syndrome in clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PSORI-CM01（YXBCM01） granule | |
| DRUG | placebo |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2014-11-01
- Completion
- 2015-10-01
- First posted
- 2014-06-03
- Last updated
- 2017-08-01
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02153840. Inclusion in this directory is not an endorsement.